Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Post discharge Nausea and Vomiting in High-risk Patients
- Post by: Claudio Pergolizzi
- February 18, 2020
- Comments off
Categories: